Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific, Inc. (TMO) is a global leader in providing science-based solutions, offering a wide range of products and services in the life sciences, analytical instruments, specialty diagnostics, and laboratory products sectors. The company's expansive portfolio includes scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents, serving customers both in the United States and internationally.
Thermo Fisher operates through four distinct segments as of end-2023:
- Analytical Technologies (17% of sales): This segment focuses on providing high-quality instruments and software solutions for various scientific applications.
- Specialty Diagnostic Products (10% of sales): This segment specializes in offering diagnostic reagents and instruments for medical and research laboratories.
- Life Science Solutions (23% of sales): This segment provides reagents, instruments, and consumables used in biological research and drug development.
- Lab Products and Services (54% of sales): This is the largest segment, encompassing laboratory supplies, equipment, and contract research organization (CRO) services.
Thermo Fisher is continually expanding its offerings and capabilities through strategic partnerships, acquisitions, and technological innovation. The company's robust financial performance underscores its leadership in the industry, driven by consistent revenue growth, strong market presence, and a commitment to advancing scientific research and healthcare.
Recent achievements include technological advancements in analytical instruments, enhanced diagnostic solutions, and expanded biopharma services, reflecting Thermo Fisher's dedication to supporting life-saving research and diagnostic processes. Thermo Fisher remains committed to delivering high-quality products and services, fostering scientific breakthroughs, and maintaining its position at the forefront of scientific innovation.
Thermo Fisher Scientific (NYSE: TMO) will announce its Q1 2021 financial results before the market opens on April 29, 2021. The company will host a conference call at 8:30 a.m. EDT to discuss its financial performance and future expectations. The call can be accessed at (833) 714-0931 within the U.S. and (778) 560-2662 internationally, with conference ID 7956359. For further details, visit www.thermofisher.com. Annual revenue exceeds $30 billion, emphasizing its leadership in the science sector.
Thermo Fisher Scientific (NYSE:TMO) has launched the Thermo Scientific AerosolSense Sampler, a new surveillance tool for rapid detection of in-air pathogens, including SARS-CoV-2. This device collects aerosol samples from ambient air, enabling subsequent laboratory analysis through PCR testing. Mark Stevenson, COO, emphasized the need for reliable solutions in various institutions to ensure safety amid ongoing pandemic risks. The AerosolSense Sampler aims to enhance monitoring capabilities while supporting decision makers in hospitals and other facilities.
Thermo Fisher Scientific (NYSE:TMO) announced over $600 million in investments to expand its bioprocessing production capabilities through 2022. This expansion aims to more than double manufacturing capacity to support biopharma customers during COVID-19 and future vaccine developments. The investment will create over 1,500 jobs across 11 sites in the Americas, Europe, and Asia. Key areas of expansion include single-use technologies, purification resins, and cell culture media production, enhancing supply chain resilience and customer support.
Thermo Fisher Scientific (NYSE: TMO) has finalized its acquisition of Mesa Biotech, enhancing its point-of-care molecular diagnostics capabilities. The Accula System, developed by Mesa, allows rapid, accurate testing for COVID-19 and other diseases, providing results in just 30 minutes. This strategic move is expected to generate approximately $200 million in revenue for Thermo Fisher in 2021. The acquisition aims to leverage Thermo Fisher's resources with Mesa's innovative technology, positioning the company to meet the growing demand for point-of-care diagnostics globally.
Thermo Fisher Scientific (NYSE: TMO) will be represented by CEO Marc N. Casper at the 41st Annual Cowen Healthcare Conference on March 3, 2021, at 10:20 a.m. EDT. The event will be held virtually, and interested parties can access the presentation through the company's website. With annual revenues exceeding $30 billion, Thermo Fisher Scientific is a leading provider of scientific services and products, aiming to make the world healthier, cleaner, and safer.
Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.26 per common share, reflecting an 18% increase from the prior $0.22 payment. The dividend is payable on April 16, 2021, to shareholders of record by March 16, 2021. With annual revenues exceeding $30 billion, Thermo Fisher continues to lead in serving scientific needs globally, supporting research and improving diagnostics through its renowned brands.
Thermo Fisher Scientific (NYSE:TMO) has acquired cell sorting technology assets from Propel Labs, enhancing its Biosciences business. This includes the Bigfoot Spectral Cell Sorter, which offers advanced sorting capabilities and faster throughput. Approximately 40 employees from Propel Labs will join Thermo Fisher, while Propel will continue operating independently. The Bigfoot technology aims to meet growing demands in cell and gene therapies, addressing significant challenges in cytometry analysis. Thermo Fisher's annual revenue exceeds $30 billion, positioning it well to improve healthcare outcomes.
Thermo Fisher Scientific (NYSE: TMO) reported impressive financial results for Q4 and full year 2020, showing a 54% increase in Q4 revenue to $10.55 billion and a 26% rise in annual revenue to $32.22 billion. Q4 GAAP diluted EPS surged 151% to $6.24, while adjusted EPS increased 100% to $7.09. Strong growth driven by $3.2 billion in COVID-19 response revenue, alongside significant investments in innovation and infrastructure, supports a robust long-term growth strategy. The company also returned $1.8 billion in capital to shareholders through buybacks and dividends.
Thermo Fisher Scientific (NYSE: TMO) announced its acquisition of Mesa Biotech, a molecular diagnostic company, for approximately $450 million in cash, with the potential for an additional $100 million based on performance milestones. Mesa Biotech specializes in rapid PCR-based testing for infectious diseases, including COVID-19 and influenza, with revenues of about $45 million in 2020. The deal, aimed at enhancing Thermo Fisher's diagnostics portfolio, is expected to close in Q1 2021, pending regulatory approvals.
FAQ
What is the current stock price of Thermo Fisher Scientific (TMO)?
What is the market cap of Thermo Fisher Scientific (TMO)?
What does Thermo Fisher Scientific, Inc. specialize in?
What are the main segments of Thermo Fisher Scientific?
How much of Thermo Fisher's sales come from Lab Products and Services?
Where does Thermo Fisher Scientific operate?
What recent achievements has Thermo Fisher Scientific made?
What is Thermo Fisher Scientific's stock symbol?
How does Thermo Fisher Scientific support scientific research?
What types of products does Thermo Fisher Scientific offer?
What is Thermo Fisher's commitment to the healthcare industry?
What sets Thermo Fisher Scientific apart in its industry?
